Gapping down
In reaction to earnings/guidance:
- PHG -11.4%
Other news:
- VALN -14.5% (Provides regulatory update on its inactivated COVID-19 vaccine candidate)
- GOSS -10.2% (announces topline results from its Phase 2 SHIFT-UC Study clinical trial studying GB004 in patients with mild-to-moderate active ulcerative colitis)
- ESTE -5.4% (Cypress Investments discloses 11.9% stake -- 13D filing )
- LLAP -5.3% (common stock offering)
- NXE -5.2% (signed Impact Benefit Agreement with the Clearwater River Dene Nation covering all phases of the Rook I Project)
- NKTR -4.8% (presentS preclinical data on NKTR-255, a novel IL-15 receptor agonist, in combination with CAR Cell therapies )
- RDW -4.6% (mixed securities shelf)
- KGC -2.6% (old a 90% interest in the Chirano mine in Ghana to Asante Gold Corp (ASGOF) for $220 mln in cash and shares)
- WBD -2.3% (mixed securities shelf)
- ICL -1.8% (details litigation updates)
- TTM -1.7% (announced a price increase across its passenger vehicles, to partially offset the rise in input cost)
- USFD -1.6% ( Sends Letter to Shareholders Highlighting Strong Preliminary First Quarter 2022 Results and Highly Qualified Board Nominees)
- ALC -1.2% (demonstrates enhanced efficiency and time savings for cataract surgeries )
Analyst comments:
- OSTK -5% (downgraded to Neutral from Buy at BofA)
- WIX -4.8% (downgraded to Underweight from Neutral at Piper Sandler)
- GOLD -3.9% (downgraded to Mkt Perform from Outperform at Bernstein)
- DE -3.3% (downgraded to Neutral from Buy at BofA),